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ABSTRACT
Backgrounds: Most of the hepatitis C virus (HCV) infections elicit poor immune responses and 75% to 85% of 
cases become chronic; therefore, the development of an effective vaccine against HCV is of paramount importance.
In this study, we aimed to evaluate co-administration of HCV non-Structural Protein 2 and IL-12 DNA vaccines in 
C57BL/6 mice. Methods: A plasmid encoding full-length HCV NS2 protein (non-structural protein 2) was 
generated and used to vaccinate mice. Negative control (an empty expression vector) was also employed to 
evaluate the background response. To investigate immune responses against vaccine, C57BL/6 mice received three 
doses of the vaccine with a two-week interval. Cellular immunity was assessed using 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide assay for lymphocyte proliferation, lactate dehydrogenase release for cytotoxic T 
lymphocyte (CTL) activity and cytokine assay. Results: The findings demonstrated that immunization of mice with 
plasmid expressing HCV NS2 induced CTL response, interferon gamma production, and lymphocyte proliferation 
compared to negative control. The results also demonstrated that co-administration of IL-12 with the HCV NS2
plasmid induced significantly better immune response in C57BL/6 mice. Conclusion: DNA vaccine encoding HCV 
NS2 is an effective candidate that can trigger CTL-based immune response against HCV. In addition, the results 
suggested that combining the DNA vaccine approach with immune stimulatory cytokines may significantly 
enhance antigen-specific immune responses. Iran. Biomed. J. 18 (1): 1-7, 2014
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INTRODUCTION
pproximately 80% of hepatitis C virus (HCV)-
infected persons fails to clear the virus and 
develop persistent infections, which frequently 
lead to chronic liver disease, fibrosis, cirrhosis, and 
hepatocellular carcinoma. Current treatments are 
effective in 50-70% of patients, and it is quite clear that 
there is an emerging need to develop effective vaccines 
against HCV [1, 2].
Non-structural protein 2 (NS2) is a 23-kDa) non-
glycosylated integral membrane protein (217 amino 
acids) [3]. The N-terminus of NS2 (residues 1-94) is 
highly hydrophobic and forms three transmembrane 
domains, while the C-terminus (residues 94-217) is 
globular and resides in the cytoplasm [4]. Interactions 
of NS2 with both structural (E1 and E2) and non-
structural (p7, NS3-4A, and NS5A) proteins suggest 
that NS2 might act as a central mediator in the HCV 
life-cycle by attracting viral proteins to the replication 
and assembly sites [5, 6]. Although the exact mode of 
NS2 action during HCV particle formation is not clear, 
it has been suggested that it is likely to act at a late step 
of assembly and maturation when NS2 would attract 
the envelope glycoproteins to the assembly site and 
interact with NS proteins during virus assembly [4, 5, 
7, 8].
At present, there are approximately 160 million 
infected individuals living with HCV worldwide, and 
there is currently no approved vaccine against HCV
A
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[9]. Therefore, a therapeutic vaccine against HCV 
would provide significant protection against the
infection. DNA vaccines have been used extensively in 
HCV vaccine research using different HCV genes [10-
13]. Among different HCV genes, non-structural 
antigens present the most genetically conserved viral 
antigen, which have been employed for induction of 
cellular immunity in animal models in different 
vaccine studies [14, 15]. Some vaccine approaches 
were tested in mice and chimpanzees, but only two 
DNA vaccine candidates had reached clinical 
evaluation [16, 17]. CICGB-230 was the first DNA 
vaccine evaluated in Cuba in Phase I of clinical trial, 
which combined plasmid expressing HCV structural 
antigens (core/E1/E2) with recombinant core protein 
particles Co.120, a protein comprising the first 120 aa 
of the HCV core antigen [16]. The second HCV DNA 
vaccine, ChronVac-C, was evaluated in a clinical 
Phase I/IIa trial in Sweden. The vaccine was based on a 
plasmid encoding NS3/NS4A under the control of 
cytomegalovirus (CMV) immediate-early promoter 
[17]. Therefore, in order to induce a stronger immune 
response, we administrated IL-12 as a genetic adjuvant. 
It has been demonstrated that Il-12 as an adjuvant has a 
critical role in inducing anti-viral and anti-tumor 
immunity in vivo [18, 19].
In the present study, we aimed to determine 
immunogenicity of NS2 and IL-12 DNA vaccines co-
administred in a mouse model. Afterwards, cellular 
immunity was analyzed against the NS2 recombinant 
protein in mice.
MATERIALS AND METHODS
Construction of plasmids and bacterial trans-
formation. Full-length sequence of NS2 (GenBank®
accession no. AB047639) was amplified using standard 
PCR protocol using NS2 forward primer (5´-
CGCCACCATGTATGACGCACCTGT GC-3´) and 
NS2 reverse primer (5´-TTAAAGGAGCTTCCACCC
CT-3´). Amplified segment was then cloned into 
pcDNA3.1 vector (Invitrogen, USA) under the control 
of the CMV promoter. Competent cells, E. coli DH5α
strain, were generated using CaCl2 method and 
subsequently transformed with empty vector (pcDNA 
3.1) or recombinant vector expressing NS2 (pcDNA 
3.1-NS2) using heat-shock method [6]. Clones were 
confirmed by colony PCR, restriction enzyme 
digestion of the purified DNA, and DNA sequencing
using CMV forward primer (5´-GGTCTATATAA
GCAGAGCTGGT-3´) and bovine growth hormone
reverse primer (5´-TAGAAGGCACA GTCGAGGC-
3´). In the previous study [6], the gene expression of 
pcDNA-FL-NS2 was evaluated and confirmed in 
eukaryotic cells (Huh-7 and 293T cells). Both 
monomeric (around 24 kDa) and dimeric (around 48
kDa) forms of the NS2 protein were detected using 
rabbit anti-NS2 antibody in Western-blotting 
experiment [6]. Plasmid pcDNA3.1-IL-12 was kindly 
provided by Dr. T. Sakai (University of Tokushima, 
Japan).
Purification of plasmid DNA. Transformed bacterial 
colonies were cultured in 5 ml Luria Bertani broth 
containing 50 g/ml ampicillin overnight. DNA
plasmids were isolated from bacteria by the alkaline
lysis procedure [20]. In brief, 250 ml Luria Bertani
broth supplemented with 50 g/ml ampicillin was
inoculated with pcDNA3.1 or pcDNA3.1-NS2, or 
pcDNA3.1-IL-12. Bacteria were cultured in a shaker 
incubator at 37C overnight, pelleted by centrifugation 
force and resuspended in the resuspension buffer
containing 25 mM Tris-HCL (pH 8.0), 10 mM EDTA
(pH 8.0), and 50 mM glucose. The bacteria were lysed 
by lysis buffer (0.2 N NaOH, 1% SDS), neutralized by 
nneutralization buffer (60 ml 5 M potassium acetate,
11.5 ml glacial acetic acid, and 28.5 ml water) and then 
centrifuged to pellet chromosomal DNA, RNA, and 
proteins. The supernatant was extracted with 
phenol/chloroform, followed by ethanol precipitation 
of the plasmid DNA. The purified DNA was run on 1%
agarose gel in TBE buffer (45 mM Tris-boric acid, 1
mM EDTA, pH 8.0), and DNA bands were visualized 
by ethidium bromide staining.
Immunization of mouse model. In this study, five
experimental groups were included (pcDNA3.1, 
pcDNA3.1-IL-12, pcDNA3.1-IL-12 + pcDNA3.1, 
pcDNA3.1-NS2, and pcDNA3.1-NS2 + pcDNA3.1-IL-
12). Nine female C57BL/6 mice (4 to 6 weeks old) per 
group were purchased from the Pasteur Institute of Iran
(Tehran) and chosen for the experiment. The mice 
were immunized three times intramuscularly with 90
μg each expression vector with a two-week interval.
The constructed DNA vaccine was injected into the
muscle cells, where the ‘inner machinery’ of the host 
cells ‘reads’ the DNA and translates it into desired 
proteins. Since these proteins are recognized as foreign
antigens, they are processed by the host cells and 
presented to the immune system. All of the mice were 
monitored for two weeks after final inoculation.
Splenocyte preparation. Two weeks after the final 
immunization, a single-cell suspension of mononuclear 
cells was obtained from immunized mice. For this 
purpose, mice were sacrificed, and the spleens were 
removed. The suspension of isolated spleen cells was 
treated with lysis buffer (0.15 M NH4Cl, 1 mM 
KHCO3, and 0.1 mM Na2EDTA, pH 7.2) in order to 
eliminate red blood cells. The cells were washed and 
resuspended in RPMI 1640 supplemented with 10%
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FBS. Cell numbers were counted using trypan blue
exclusion method, and the percentage of cell viability 
was calculated.
3-(4,5-dimethylthiazol-2-yl) -2,5-diphenyl tetra-
zolium bromide (MTT) assay. The MTT assay was 
performed to measure lymphocyte proliferation. The 
splenocytes were cultured at a concentration of 2 × 105
cells/well in 96-well plates in the presence of 1 μg/ml 
NS2 antigen as prepared from our previous study [6], 5
μg/ml PHA (Sigma Chemicals, USA), or RPMI-1640
media. The assay is based on the capacity of 
mitochondrial dehydrogenase enzymes in splenocytes
to convert the yellow water-soluble substrate, MTT,
into a dark blue formazan product, which is insoluble 
in water. A solubilization solution was then added to 
dissolve the insoluble purple formazan product into a 
colored solution. The absorbance of colored solution 
was quantified by its measurement at a wavelength of
570 nm by an ELISA reader. All tests were performed 
in triplicate for each mouse, and results were expressed 
as stimulation index, which was defined as the ratio of
the mean absorbance of antigen-stimulated cells to that 
of unstimulated ones [21].
Lactate dehydrogenase (LDH) cytotoxicity detection 
activity. HCV-specific cytotoxic T lymphocyte (CTL) 
activity was measured by LDH release assay using 
LDH Cytotoxicity Detection Kit (Takara, Japan)
according to the manufacturer’s instruction. LDH is an 
intracellular enzyme that is found in the cells of many 
body tissues. Two weeks after the last inoculation, a 
single-cell suspension of spleno-cytes was prepared 
and used as effector cells. A precise number of EL4
cells (4 × 104) in a volume of 100 μl were incubated 
with effector cells (100 μl) at different effector/target 
ratios. For preparation of the target cells, EL4 cells 
were stimulated with 1 µg/ml HCV NS2 antigen. After 
incubation, the microplates were centrifuged at 250 ×g 
for 10 min. Supernatant per each well (100 µl) was 
carefully removed and transferred into corresponding 
wells of an optically clear 96-well flat bottom 
microplate. Next, 100 μl Solution C (reaction mixture) 
was added to each well, and it was allowed 30 min for 
color development. Optical density was measured at a 
wavelength of 490 nm by an ELISA reader; the 
reference wavelength was 630 nm. Data were 
normalized to maximal (Triton X100 lysis of target 
cells alone) and minimal (target cells alone) lyses. The 
percentage of cytotoxicity was then calculated as 
follows: [(test sample – low control)/(high control –
low control)] × 100%. All determinations were 
performed in triplicate [22].
Cytokine secretion assay. Two weeks after the last
immunization, mononuclear cells from immunized
mice in 1.5 ml RPMI-1640) were pulsed with NS2
antigen in 5% CO2 at 37°C. Cell-free supernatants 
were collected and analyzed for the incidence of IFN-γ 
and IL-4 using Sandwich-Based ELISA kits (R&D 
Systems, Minneapolis, USA) following manufacturer’s 
instruction. All tests were performed in triplicate for 
each mouse.
Statistical analysis. In vitro immune response data 
were collected from five individual experiments and all 
the experiments were performed in triplicates. The data 
were analyzed by SPSS 18 using test of homogeneity 
of variances as well as multiple comparisons and 
ANOVA tests. A P value of 0.05 was considered 
statistically signiﬁcant. Each data point represents the 
mean ± SD of a triplicate.
RESULTS
Plasmid extraction. The bacteria with correct 
plasmids were cultured in a large scale at 37°C for 16-
18 hours. Recombinant plasmids were isolated and 
confirmed by restriction enzyme digestion and DNA 
sequencing (Fig. 1). After plasmid extraction, DNA 
concentration was determined using a Picodrop
(PicoDrop, UK) at 260 nm. In addition, purity 
considered as the relative DNA/protein content was 
estimated by the same method, and expressed as the 
ratio of A260 /A280 with a value of 1.8 as expected.
The extracted plasmids were also analyzed on 0.8%
agarose gel electrophoresis.
Lymphocyte pro-liferation. Groups of C57BL/6
mice were administrated intramuscularly. Two weeks 
after the last vaccination, mice were euthanized, and 
the splenocytes were aseptically separated. Splenocytes 
were re-stimulated in vitro and then lymphocyte 
proliferation was measured by MTT assay.  As shown 
in Figure 2, mice immunization with NS2 + IL-12
(3.44 ± 0.10) and NS2 group control (2.03 ± 0.34) 
revealed better proliferation response than IL-12 group 
and negative   groups.   The   results  also  
demonstrated a 
Fig. 1. Schematic representation of the pcDNA-NS2
construct. NS2 gene (GenBank® accession no. AB047639) was  
under  the  control  of  the  CMV  promoter  in  the  pcDNA3.1
expression plasmid.
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Fig. 2. HCV NS2-specific lymphocyte proliferation. Two 
weeks after the last administration, the spleens were removed 
and lymphocyte proliferation was evaluated by the MTT assay. 
Data were expressed as means ± SD (n = 9). Data was 
considered statistically significant at P<0.05.
significant difference in the lymphocyte proliferation 
index in the NS2 + IL-12 group compared with the 
NS2 group alone (P>0.05) (Fig. 2).
Cytotoxic T lymphocyte responses. To evaluate the 
specific CTL in the various groups of immunized mice,
the LDH release was measured. Splenocytes from 
vaccinated mice were re-stimulated in vitro. As seen in 
Figure 3, LDH activity was significantly increased in
pcDNA3.1-NS2 group as compared to the control 
group (P<0.05).   The   results showed no significant 
difference in LDH leakage between NS2 and NS2 +
IL-12; therefore, IL-12 did not significantly augment
CTL activities. These results indicated that mice 
immunized with NS2 or NS2 + IL-12 developed strong 
specific CTL responses.
       
Fig. 3. CTL activity. CTL assays to demonstrate lymphocytes 
in mice vaccinated with different DNA vaccines using 
quantitative measurement of LDH release. Data were collected 
from LDH results at various E/T ratios and expressed as percent 
cytotoxicity ± SD (n = 9). Data was considered statistically 
significant at P<0.05.
Cytokine assay. Splenocytes from all the five groups 
of mice were assayed for their IFN-γ and IL-4 cytokine 
levels in the supernatants. The spleen cells of mice 
vaccinated with pcDNA3.1-NS2 plasmid showed 
higher levels of cytokines compared with those of mice 
administered with empty vector (Fig. 4). Compared 
with high levels of IFN-γ secretion, spleen cells from 
the pcDNA3.1-NS2 group produced relatively lower 
levels of IL-4, and booster immunization did not 
increase IL-4 secretion (Fig. 4).
Fig. 4. The concentrations (pg/ml) of Th1-type cytokine of
IFN-Gamma and Th2-type cytokine of IL-4 in the supernatants. 
Collected supernatants were evaluated for the IFN-γ and IL-4
release using ELISA. The concentration of the cytokines was 
determined by comparison to a standard curve of serially diluted 
positive control samples. Bars = means SD. Each sample was 
examined in triplicate and the results were representative of two 
independent experiments (P<0.05).
DISCUSSION
In present study, we have demonstrated that co-
administration of DNA vaccine encoding HCV NS2
gene with plasmid containing IL-12 adjuvant is able to 
induce a significant cellular immune response in 
C57BL/6 mice. With the high global disease burden 
and public health impact of hepatitis C, development of 
an effective vaccine is of major significance. An 
efficient vaccine against HCV infection requires 
vigorous and focused CD8+ T-cell responses against 
viral antigens [23]. However, many challenging 
obstacles lie ahead of this goal. Given the importance 
of the NS2 protein in the HCV life-cycle, we chose 
NS2 as a vaccine candidate against HCV. For this 
purpose, the immunogenicity of HCV-NS2 DNA 
vaccine with or without IL-12 adjuvant in the induction 
of cellular immune responses was evaluated in 
C57BL/6 mice. Our results showed that IL-12 could 
boost the MTT and LDH responses as compared with 
control groups. In addition, NS2 + IL-12 significantly 
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induced greater lymphocyte proliferation and 
cytotoxicity (P<0.05). As shown in Figure 2, the NS2
+ IL-12 group experienced the greatest lymphocyte 
proliferation, indicating that vaccination with NS2 + 
IL-12 induces the proliferation of specific 
lymphocytes. As illustrated in Figures 2-4, cellular 
immune responses including the amount of released 
LDH, IFN-γ production, and lymphocyte proliferation 
have been increased by the adjuvant.
DNA vaccines have a number of advantages over 
other vaccines, including the ease to generate and 
manipulate as well as its potency in stimulating Th1-
biased immune responses against an encoded antigen.
Kwon et al. [24] have demonstrated that co-injection of 
plasmid expressing IL-12 and DNA vaccine encoding 
antigen genes resulted in enhanced Th1 and CTL 
responses and a decrease in antibody production.
Therefore, in present study, we evaluated 
immunogenicity of DNA vaccine encoding NS2 in 
combination with plasmid encoding IL-12 as a genetic 
adjuvant.
DNA-based immunization can induce lympho-
proliferative responses against the structural proteins 
core [25-27], E1 [28], E2 [28], and the non-structural 
proteins NS3, NS4, and NS5 in mice [11] and buffalo 
rats [29]. Various methods have been used to augment
the cellular immune responses [24, 26]. It has been 
shown that IL-12 drives strong TH1-based cellular 
immune responses in small animal models [30] and
non-human primate models of vaccination when used 
as genetic adjuvant [31].
Immunization against HCV will involve the 
generation of cell-mediated immunity to mediate 
killing or down-regulation of infected cells [32]. One 
of approaches that enhance DNA-based immune 
responses is the co-administration of cytokine 
expressing plasmids with DNA vaccine expressing the 
gene [25]. In this respect, IL-12-encoding plasmids are 
particularly promising, since they stimulate TH1
responses [18, 33] and increase the induction of 
antigen-speciﬁc CD8 + CTL [33, 34]. In several 
studies, co-delivery of plasmids encoding IL-12 with 
DNA vaccines induced enhanced protection against 
viral infections and tumors [18, 34].
TH2 and TH1 cytokines have different roles in 
polarization of immune responses. TH2 cytokines 
preferentially drive humoral immunity, whereas TH1
cytokines drive induction of cellular immunity. To 
understand the role of IL-12 in development of 
immune responses, we examined the effect of co-
injection of NS2 DNA vaccine with and without IL-12
on Th1/Th2 ratio. As shown in Figure 4, co-inoculation
of IL-12 signiﬁcantly augmented the production of 
IFN-γ (TH1-type) compared with NS2 DNA vaccine 
only. In contrast, the IL-4 (TH2-type) level was not 
significantly increased by IL-12 co-inoculation. The 
production of IFN- has a dominant effect in enhancing 
the ability of phagocytic cells to produce IL-12. IL-12
also increases the production of IFN-, creating a 
positive reinforcement loop. Early induction of IFN-
by IL-12 expression is also the key to the start the 
innate immune responses [35].
Our results indicate that pcDNA3.1-NS2 vaccination 
significantly induces cellular immune responses
(cytokine secretion, CTL, and T-helper lymphocyte 
responses) in C57BL/6 mice. It seems that the HCV-
NS2 could be an effective candidate gene to induce 
cellular immune responses against HCV.
In conclusion, results presented in this study suggest 
that co-immunization of IL-12 with the NS2 DNA
vaccine enhances the cellular immune response of the 
NS2 DNA vaccine and augments the NS2 vaccine 
ability to protect efficiently against HCV. These
outcomes have noticeable concepts for prophylactic 
and/or therapeutic vaccines.
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